TNNI3K anticorps

N° du produit ABIN1387081

Cet anticorps Lapin Polyclonal détecte spécifiquement TNNI3K dans WB, IF (p) et IHC (p). Il présente une réactivité envers Humain, Souris et Rat.

Aperçu rapide pour TNNI3K anticorps (ABIN1387081)

Antigène: TNNI3K (TNNI3 Interacting Kinase (TNNI3K))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp TNNI3K est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-TNNI3K anticorps

Réactivité croisée: Humain, Souris, Rat

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human TNNI3K

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
IHC-P 1:200-400
IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Détails sur TNNI3K

Antigène: TNNI3K (TNNI3 Interacting Kinase (TNNI3K))

Autre désignation: TNNI3K

Sujet:

Synonyms: Cardiac ankyrin repeat kinase, CARK, MGC142099, MGC33828, Serine/threonine protein kinase TNN13K, Serine/threonine-protein kinase TNNI3K, TNI3K_HUMAN, TNNI3 interacting kinase, TNNI3-interacting kinase, Tnni3k.

Background: TNNI3K, also known as CARK, is a 936 amino acid serine/threonine-protein kinase that is highly expressed in heart. Overexpression of TNNI3K leads to improved cardiac function by enhancing beating frequency and increasing contractile force and epinephrine response. TNNI3K suppresses phosphorylation of cardiac troponin I and p38/JNK-mediated apoptosis, therefore protecting the myocardium from ischemic injury. Administration of TNNI3K to mice with myocardial infarction improves cardiac performance and attentuates ventricular remodeling, suggesting that TNNI3K could be a promising target in the treatment of cardiac diseases. There are four isoforms of TNNI3K that are produced as a result of alternative splicing events.

ID gène: 51086